Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

A pilot study on the usefulness of peripheral blood flow cytometry for the diagnosis of lower risk myelodysplastic syndromes: the "MDS thermometer".

Aires A, Teixeira MDA, Lau C, Moreira C, Spínola A, Mota A, Freitas I, Coutinho J, Lima M.

BMC Hematol. 2018 Mar 13;18:6. doi: 10.1186/s12878-018-0101-8. eCollection 2018.

2.

Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes.

Drusbosky LM, Cogle CR.

Curr Hematol Malig Rep. 2017 Oct;12(5):478-483. doi: 10.1007/s11899-017-0412-z. Review.

3.

Diagnostics and Prognostication of Myelodysplastic Syndromes.

Zini G.

Ann Lab Med. 2017 Nov;37(6):465-474. doi: 10.3343/alm.2017.37.6.465. Review.

4.

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G.

Blood. 2017 Sep 28;130(13):1514-1522. doi: 10.1182/blood-2017-06-788497. Epub 2017 Aug 3.

PMID:
28774880
5.

The association of ferritin with cardiovascular and all-cause mortality in community-dwellers: The English longitudinal study of ageing.

Kadoglou NPE, Biddulph JP, Rafnsson SB, Trivella M, Nihoyannopoulos P, Demakakos P.

PLoS One. 2017 Jun 7;12(6):e0178994. doi: 10.1371/journal.pone.0178994. eCollection 2017.

6.

Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.

Kennedy JA, Ebert BL.

J Clin Oncol. 2017 Mar 20;35(9):968-974. doi: 10.1200/JCO.2016.71.0806. Epub 2017 Feb 13. Review.

7.

Myelodysplastic Syndromes: Updates and Nuances.

Dao KT.

Med Clin North Am. 2017 Mar;101(2):333-350. doi: 10.1016/j.mcna.2016.09.006. Review.

8.

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy.

Prebet T, Toma A, Cluzeau T, Sekeres MA, Vey N, Park S, Al Ali N, Sugrue MM, Komrokji R, Fenaux P, Gore SD.

Oncotarget. 2017 Jun 6;8(23):37866-37874. doi: 10.18632/oncotarget.15200.

9.

Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).

DeZern AE, Zeidan AM, Barnard J, Hand W, Al Ali N, Brown F, Zimmerman C, Roboz GJ, Garcia-Manero G, Steensma DP, Komrokji RS, Sekeres MA; Evans MDS Clinical Research Consortium.

Leuk Lymphoma. 2017 Jun;58(6):1325-1331. doi: 10.1080/10428194.2016.1246726. Epub 2016 Oct 24.

10.

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.

Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H.

BMC Cancer. 2016 Aug 19;16:652. doi: 10.1186/s12885-016-2710-6.

11.

Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).

Yao CY, Hou HA, Lin TY, Lin CC, Chou WC, Tseng MH, Chiang YC, Liu MC, Liu CW, Kuo YY, Wu SJ, Liao XW, Lin CT, Ko BS, Chen CY, Hsu SC, Li CC, Huang SY, Yao M, Tang JL, Tsay W, Liu CY, Tien HF.

Oncotarget. 2016 Sep 27;7(39):63177-63188. doi: 10.18632/oncotarget.11050.

12.

Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators.

Qiu J, Zhou B, Thol F, Zhou Y, Chen L, Shao C, DeBoever C, Hou J, Li H, Chaturvedi A, Ganser A, Bejar R, Zhang DE, Fu XD, Heuser M.

RNA. 2016 Oct;22(10):1535-49. doi: 10.1261/rna.056101.116. Epub 2016 Aug 4.

13.

Time-dependent changes in mortality and transformation risk in MDS.

Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Levis A, Luebbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SM, Miyazaki Y, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Blood. 2016 Aug 18;128(7):902-10. doi: 10.1182/blood-2016-02-700054. Epub 2016 Jun 22.

14.

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.

Belickova M, Vesela J, Jonasova A, Pejsova B, Votavova H, Merkerova MD, Zemanova Z, Brezinova J, Mikulenkova D, Lauermannova M, Valka J, Michalova K, Neuwirtova R, Cermak J.

Oncotarget. 2016 Jun 14;7(24):36266-36279. doi: 10.18632/oncotarget.9200.

15.
16.

Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Cogle CR, Scott BL, Boyd T, Garcia-Manero G.

Oncologist. 2015 Dec;20(12):1404-12. doi: 10.1634/theoncologist.2015-0165. Epub 2015 Oct 13. Review.

17.

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.

Garcia-Manero G, Gore SD, Kambhampati S, Scott B, Tefferi A, Cogle CR, Edenfield WJ, Hetzer J, Kumar K, Laille E, Shi T, MacBeth KJ, Skikne B.

Leukemia. 2016 Apr;30(4):889-96. doi: 10.1038/leu.2015.265. Epub 2015 Oct 7.

18.

Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better?

Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS; MDS Clinical Research Consortium.

Am J Hematol. 2015 Aug 11. doi: 10.1002/ajh.24170. [Epub ahead of print]

19.

Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?

Nazha A, Sekeres MA, Gore SD, Zeidan AM.

Oncologist. 2015 Sep;20(9):1069-76. doi: 10.1634/theoncologist.2015-0067. Epub 2015 Jul 20. Review.

20.

Deferasirox in a refractory anemia after other treatment options: case report and literature review.

Manduzio P.

Clin Case Rep. 2015 Jun;3(6):361-7. doi: 10.1002/ccr3.262. Epub 2015 Mar 29.

Supplemental Content

Support Center